

CORhum - Morbidity-mortality of COVID-19 in patients with chronic rheumatic disorder treated with immunosuppressants

Head :LETAROUILLY Jean-Guillaume

Last update : 05/05/2021 | Version : 1 | ID : 73495

General

Identification

Detailed name Morbidity-mortality of COVID-19 in patients with chronic rheumatic disorder treated with immunosuppressants

Sign or acronym CORhum

CNIL registration number, number and date of CPP agreement, AFSSAPS (French Health Products Safety Agency) authorisation CNIL 2021796 v 0, CPP CPP2020-06-056b, NCT04426279

General Aspects

Medical area Internal medicine
Rheumatology

Study in connection with Covid-19 Yes

Pathology (details) systemic lupus erythematosus, spondyloarthritis, rheumatoid arthritis

Keywords systemic lupus erythematosus, spondyloarthritis, chronic rheumatic disorder, biological therapy, rheumatoid arthritis, immunosuppressants

Scientific investigator(s) (Contact)

Name of the director LETAROUILLY

Surname Jean-Guillaume

Address Service de Rhumatologie
Hôpital Roger Salengro
Rue Emile Laine
59037 Lille

Phone 320446926

Email jeanguillaume.letarouilly@chu-lille.fr

Organization Lille University Hospital

Collaborations

Participation in projects, networks and consortia Yes

Funding

Governance of the database

Sponsor(s) or organisation(s) responsible Lille University Hospital

Organisation status Public

Additional contact

Main features

Type of database

Type of database Study databases

Study databases (details) Not-repeated cross-sectional studies (except case control studies)

Database recruitment is carried out as part of an interventional study No

Database objective

Main objective Estimate morbidity-mortality associated with COVID-19 in patients with chronic rheumatic disorder (CRD) receiving immunosuppressants (IS).

Inclusion criteria Patients with RA on csDMARD +/- bDMARD or tsDMARD +/- corticosteroid therapy fulfilling 2010 ACR/EULAR classification criteria? Patients with SpA receiving bDMARD or tsDMARD +/- csDMARD +/- non-steroidal anti-inflammatory drugs fulfilling ASAS classification criteria? Patients with SLE receiving hydroxychloroquine +/- csDMARD +/- corticosteroid therapy +/- bDMARD fulfilling 2019 ACR/EULAR classification criteria

Population type

Age Adulthood (19 to 24 years)
Adulthood (25 to 44 years)
Adulthood (45 to 64 years)
Elderly (65 to 79 years)

Population covered Sick population

Pathology L93 - Lupus erythematosus

M05-M14 - Inflammatory polyarthropathies

Gender Male
Woman

Geography area Local

French regions covered by the database Nord - Pas-de-Calais Picardie

Data collection

Dates

Size of the database

Size of the database (number of individuals) [500-1000[individuals

Details of the number of individuals 1500

Data

Database activity Current data collection

Type of data collected Clinical data

Presence of a biobank No

Procedures

Followed pathology

Promotion and access

Promotion

Access